Evidence map›Paper›PMID 37751075›Full record

SynthesisPharmacoEconomics2024

Economic Evaluations Comparing Deep Brain Stimulation to Best Medical Therapy for Movement Disorders: A Meta-Analysis.

Melissa Lannon, Taylor Duda, Alexander Mastrolonardo, Ellissa Huang, Amanda Martyniuk, Forough Farrokhyar, Feng Xie, Mohit Bhandari, Suneil K Kalia, Sunjay Sharma

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in PharmacoEconomics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Noninvasive Therapies: A Forthcoming Approach to Parkinson's Treatment.CNS & neurological disorders drug targets · 2025
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Melissa LannonDivision of Neurosurgery, McMaster University, 237 Barton Street East, Hamilton, ON, Canada. melissa.lannon@medportal.ca.ORCID 0000-0003-2691-2692
Taylor DudaDivision of Neurosurgery, McMaster University, 237 Barton Street East, Hamilton, ON, Canada.
Alexander MastrolonardoMichael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.
Ellissa HuangMichael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.
Amanda MartyniukDivision of Neurosurgery, McMaster University, 237 Barton Street East, Hamilton, ON, Canada.
Forough FarrokhyarDepartment of Health, Evidence, Impact, McMaster University, Hamilton, ON, Canada.
Feng XieDepartment of Health, Evidence, Impact, McMaster University, Hamilton, ON, Canada.
Mohit BhandariDepartment of Health, Evidence, Impact, McMaster University, Hamilton, ON, Canada.
Suneil K KaliaDivision of Neurosurgery, University of Toronto, Toronto, ON, Canada.
Sunjay SharmaDivision of Neurosurgery, McMaster University, 237 Barton Street East, Hamilton, ON, Canada.
McMaster University · CAImpact · CAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMovement disorders (Parkinson's disease, essential tremor, primary dystonia) are a debilitating group of conditions that are progressive in nature. The mainstay of treatment is best medical therapy; however, a number of surgical therapies are available, including deep brain stimulation. Economic evaluations are an important aspect of evidence to inform decision makers regarding funding allocated to these therapies.

objectiveThis systematic review and meta-analysis evaluated the cost effectiveness of including deep brain stimulation compared with best medical therapy for movement disorder indications in the adult population.

methodsOvid Medical Literature Analysis and Retrieval System Online, Embase, and Cochrane Central Register of Controlled Trials were queried. Only economic evaluations reporting incremental cost-effectiveness ratios for including deep brain stimulation versus best medical therapy for movement disorders were included. Studies were reviewed in duplicate for inclusion and data abstraction. Data were harmonized using the Consumer Price Index and Purchasing Power Parity to standardize values to 2022 US dollars. For inclusion in meta-analyses, studies were required to have sufficient data available to calculate an estimate of the incremental net benefit. Meta-analyses of pooled incremental net benefit based on the time horizon were performed. The study was registered at PROSPERO (CRD42022335436).

resultsThere were 2190 studies reviewed, with 14 economic evaluations included following a title/abstract and full-text review. Only studies considering Parkinson's disease were available for the meta-analysis. Quality of the identified studies was low, with moderate transferability to the American Healthcare System, and certainty of evidence was low. However, studies with a longer time horizon (15 years to lifetime) were found to have significant positive incremental net benefit (indicating cost effectiveness) for including deep brain stimulation with a mean difference of US$40,504.81 (95% confidence interval 2422.42-78,587.19).

conclusionsDeep brain stimulation was cost effective for Parkinson's disease when considered over the course of the patient's remaining life after implantation.

trial registrationClinical Trial Registration: PROSPERO (CRD42022335436).

Indexed as

Deep Brain StimulationMovement DisordersCost-Benefit AnalysisHumansParkinson Disease

Identifiers

PMID37751075
OpenAlexW4387033463

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.